Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Microenvironment
Published in: Cancer Microenvironment 3/2015

01-12-2015 | Original Article

The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment

Authors: Ronit Vogt Sionov, Zvi G. Fridlender, Zvi Granot

Published in: Cancer Microenvironment | Issue 3/2015

Login to get access

Abstract

Neutrophils are myeloid cells that constitute 50–70 % of all white blood cells in the human circulation. Traditionally, neutrophils are viewed as the first line of defense against infections and as a major component of the inflammatory process. In addition, accumulating evidence suggest that neutrophils may also play a key role in multiple aspects of cancer biology. The possible involvement of neutrophils in cancer prevention and promotion was already suggested more than half a century ago, however, despite being the major component of the immune system, their contribution has often been overshadowed by other immune components such as lymphocytes and macrophages. Neutrophils seem to have conflicting functions in cancer and can be classified into anti-tumor (N1) and pro-tumor (N2) sub-populations. The aim of this review is to discuss the varying nature of neutrophil function in the cancer microenvironment with a specific emphasis on the mechanisms that regulate neutrophil mobilization, recruitment and activation.
Literature
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
Fioretti F, Fradelizi D, Stoppacciaro A, Ramponi S, Ruco L, Minty A, Sozzani S, Garlanda C, Vecchi A, Mantovani A (1998) Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J Immunol 161(1):342–346PubMed
13.
14.
Stoppacciaro A, Melani C, Parenza M, Mastracchio A, Bassi C, Baroni C, Parmiani G, Colombo MP (1993) Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma. J Exp Med 178(1):151–161PubMedCrossRef
15.
Mantovani A, Cassatella MA, Costantini C, Jaillon S (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11(8):519–531. doi:10.​1038/​nri3024 PubMedCrossRef
16.
Cavallo F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, Modesti A, Forni G (1992) Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 149(11):3627–3635PubMed
17.
Suttmann H, Riemensberger J, Bentien G, Schmaltz D, Stockle M, Jocham D, Bohle A, Brandau S (2006) Neutrophil granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 66(16):8250–8257. doi:10.​1158/​0008-5472.​CAN-06-1416 PubMedCrossRef
18.
19.
Midorikawa Y, Yamashita T, Sendo F (1990) Modulation of the immune response to transplanted tumors in rats by selective depletion of neutrophils in vivo using a monoclonal antibody: abrogation of specific transplantation resistance to chemical carcinogen-induced syngeneic tumors by selective depletion of neutrophils in vivo. Cancer Res 50(19):6243–6247PubMed
20.
21.
22.
23.
Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh L, Mousa S, Quezado M, Herscher LL, Van Waes C (1999) Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5(6):1369–1379PubMed
24.
Chen Z, Colon I, Ortiz N, Callister M, Dong G, Pegram MY, Arosarena O, Strome S, Nicholson JC, Van Waes C (1998) Effects of interleukin-1alpha, interleukin-1 receptor antagonist, and neutralizing antibody on proinflammatory cytokine expression by human squamous cell carcinoma lines. Cancer Res 58(16):3668–3676PubMed
25.
Arii K, Tanimura H, Iwahashi M, Tsunoda T, Tani M, Noguchi K, Mizobata S, Hotta T, Nakamori M, Yamaue H (2000) Neutrophil functions and cytokine production in patients with gastric cancer. Hepatogastroenterology 47(31):291–297PubMed
26.
Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, Qu X, Yu L, Ross J, Korsisaari N, Cao T, Bou-Reslan H, Kallop D, Weimer R, Ludlam MJ, Kaminker JS, Modrusan Z, van Bruggen N, Peale FV, Carano R, Meng YG, Ferrara N (2010) Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A 107(50):21248–21255. doi:10.​1073/​pnas.​1015855107 PubMedPubMedCentralCrossRef
27.
Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, Shono Y, Kitabatake M, Kakimi K, Mukaida N, Matsushima K (2008) Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 111(12):5457–5466. doi:10.​1182/​blood-2008-01-136895 PubMedCrossRef
28.
29.
Ninck S, Reisser C, Dyckhoff G, Helmke B, Bauer H, Herold-Mende C (2003) Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer 106(1):34–44. doi:10.​1002/​ijc.​11188 PubMedCrossRef
30.
31.
32.
33.
34.
35.
Schwandt A, Garcia JA, Elson P, Wyckhouse J, Finke JH, Ireland J, Triozzi P, Zhou M, Dreicer R, Rini BI (2011) Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining. J Clin Immunol 31(4):690–698. doi:10.​1007/​s10875-011-9530-x PubMedCrossRef
36.
Yamamoto M, Kamigaki T, Yamashita K, Hori Y, Hasegawa H, Kuroda D, Moriyama H, Nagata M, Ku Y, Kuroda Y (2009) Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer. Oncol Rep 22(2):337–343PubMed
37.
38.
39.
Noguera R, Nieto OA, Tadeo I, Farinas F, Alvaro T (2012) Extracellular matrix, biotensegrity and tumor microenvironment. An update and overview. Histol Histopathol 27(6):693–705PubMed
40.
41.
Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, Kollias G, Balkwill F (1999) Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 5(7):828–831. doi:10.​1038/​10552 PubMedCrossRef
42.
43.
44.
45.
Jing Y, Ma N, Fan T, Wang C, Bu X, Jiang G, Li R, Gao L, Li D, Wu M, Wei L (2011) Tumor necrosis factor-alpha promotes tumor growth by inducing vascular endothelial growth factor. Cancer Invest 29(7):485–493. doi:10.​3109/​07357907.​2011.​597812 PubMed
46.
Tzeng HE, Tsai CH, Chang ZL, Su CM, Wang SW, Hwang WL, Tang CH (2013) Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma. Biochem Pharmacol 85(4):531–540. doi:10.​1016/​j.​bcp.​2012.​11.​021 PubMedCrossRef
47.
Whalen GF (1990) Solid tumours and wounds: transformed cells misunderstood as injured tissue? Lancet 336(8729):1489–1492PubMedCrossRef
48.
49.
Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23(11):549–555PubMedCrossRef
50.
51.
52.
53.
Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, Vago L, Nebuloni M, Mantovani A, Sica A (2006) A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107(5):2112–2122. doi:10.​1182/​blood-2005-01-0428 PubMedCrossRef
54.
Kuang DM, Peng C, Zhao Q, Wu Y, Zhu LY, Wang J, Yin XY, Li L, Zheng L (2010) Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients. J Immunol 185(3):1544–1549. doi:10.​4049/​jimmunol.​0904094 PubMedCrossRef
55.
56.
Laan M, Cui ZH, Hoshino H, Lotvall J, Sjostrand M, Gruenert DC, Skoogh BE, Linden A (1999) Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 162(4):2347–2352PubMed
57.
58.
59.
60.
Houghton AM (2010) The paradox of tumor-associated neutrophils: fueling tumor growth with cytotoxic substances. Cell Cycle 9(9):1732–1737PubMedCrossRef
61.
Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, Cassatella MA (2000) The neutrophil as a cellular source of chemokines. Immunol Rev 177:195–203PubMedCrossRef
62.
Pelletier M, Maggi L, Micheletti A, Lazzeri E, Tamassia N, Costantini C, Cosmi L, Lunardi C, Annunziato F, Romagnani S, Cassatella MA (2010) Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 115(2):335–343. doi:10.​1182/​blood-2009-04-216085 PubMedCrossRef
63.
Liang SC, Long AJ, Bennett F, Whitters MJ, Karim R, Collins M, Goldman SJ, Dunussi-Joannopoulos K, Williams CM, Wright JF, Fouser LA (2007) An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J Immunol 179(11):7791–7799PubMedCrossRef
64.
65.
Fridlender ZG, Sun J, Mishalian I, Singhal S, Cheng G, Kapoor V, Horng W, Fridlender G, Bayuh R, Worthen GS, Albelda SM (2012) Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS One 7(2):e31524. doi:10.​1371/​journal.​pone.​0031524 PubMedPubMedCentralCrossRef
66.
67.
68.
Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, Kim SJ, Parijs LV, Greenberg NM, Liu V, Guo Y, Lee C (2005) Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res 65(5):1761–1769. doi:10.​1158/​0008-5472.​CAN-04-3169 PubMedCrossRef
69.
Gholamin M, Moaven O, Memar B, Farshchian M, Naseh H, Malekzadeh R, Sotoudeh M, Rajabi-Mashhadi MT, Forghani MN, Farrokhi F, Abbaszadegan MR (2009) Overexpression and interactions of interleukin-10, transforming growth factor beta, and vascular endothelial growth factor in esophageal squamous cell carcinoma. World J Surg 33(7):1439–1445. doi:10.​1007/​s00268-009-0070-y PubMedCrossRef
70.
Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP (1999) Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 5(10):2963–2970PubMed
71.
72.
Jayaraman P, Parikh F, Lopez-Rivera E, Hailemichael Y, Clark A, Ma G, Cannan D, Ramacher M, Kato M, Overwijk WW, Chen SH, Umansky VY, Sikora AG (2012) Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol 188(11):5365–5376. doi:10.​4049/​jimmunol.​1103553 PubMedPubMedCentralCrossRef
73.
74.
Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30(3):377–386. doi:10.​1093/​carcin/​bgp014 PubMedCrossRef
75.
76.
McKallip R, Li R, Ladisch S (1999) Tumor gangliosides inhibit the tumor-specific immune response. J Immunol 163(7):3718–3726PubMed
77.
Hossain DM, Mohanty S, Ray P, Das T, Sa G (2012) Tumor gangliosides and T cells: a deadly encounter. Front Biosci (Schol Ed) 4:502–519CrossRef
78.
79.
Wojtowicz-Praga S (2003) Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs 21(1):21–32PubMedCrossRef
80.
81.
Barcellos-Hoff MH, Dix TA (1996) Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol 10(9):1077–1083PubMed
82.
83.
84.
Lechner MG, Megiel C, Russell SM, Bingham B, Arger N, Woo T, Epstein AL (2011) Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med 9:90. doi:10.​1186/​1479-5876-9-90 PubMedPubMedCentralCrossRef
85.
86.
Malipiero U, Koedel U, Pfister HW, Leveen P, Burki K, Reith W, Fontana A (2006) TGFbeta receptor II gene deletion in leucocytes prevents cerebral vasculitis in bacterial meningitis. Brain 129(Pt 9):2404–2415. doi:10.​1093/​brain/​awl192 PubMedCrossRef
87.
Parekh T, Saxena B, Reibman J, Cronstein BN, Gold LI (1994) Neutrophil chemotaxis in response to TGF-beta isoforms (TGF-beta 1, TGF-beta 2, TGF-beta 3) is mediated by fibronectin. J Immunol 152(5):2456–2466PubMed
88.
Fava RA, Olsen NJ, Postlethwaite AE, Broadley KN, Davidson JM, Nanney LB, Lucas C, Townes AS (1991) Transforming growth factor beta 1 (TGF-beta 1) induced neutrophil recruitment to synovial tissues: implications for TGF-beta-driven synovial inflammation and hyperplasia. J Exp Med 173(5):1121–1132PubMedCrossRef
89.
Reibman J, Meixler S, Lee TC, Gold LI, Cronstein BN, Haines KA, Kolasinski SL, Weissmann G (1991) Transforming growth factor beta 1, a potent chemoattractant for human neutrophils, bypasses classic signal-transduction pathways. Proc Natl Acad Sci U S A 88(15):6805–6809PubMedPubMedCentralCrossRef
90.
91.
Smith WB, Noack L, Khew-Goodall Y, Isenmann S, Vadas MA, Gamble JR (1996) Transforming growth factor-beta 1 inhibits the production of IL-8 and the transmigration of neutrophils through activated endothelium. J Immunol 157(1):360–368PubMed
92.
Bierie B, Stover DG, Abel TW, Chytil A, Gorska AE, Aakre M, Forrester E, Yang L, Wagner KU, Moses HL (2008) Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res 68(6):1809–1819. doi:10.​1158/​0008-5472.​CAN-07-5597 PubMedCrossRef
93.
94.
95.
96.
Schrey MP, Patel KV (1995) Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br J Cancer 72(6):1412–1419PubMedPubMedCentralCrossRef
97.
Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62(3):632–635PubMed
98.
Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O’Neill A, Mier J, Ochoa AC (2005) Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65(8):3044–3048. doi:10.​1158/​0008-5472.​CAN-04-4505 PubMed
99.
100.
Obermajer N, Wong JL, Edwards RP, Odunsi K, Moysich K, Kalinski P (2012) PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunol Investig 41(6–7):635–657. doi:10.​3109/​08820139.​2012.​695417 CrossRef
101.
Plescia OJ, Smith AH, Grinwich K (1975) Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci U S A 72(5):1848–1851PubMedPubMedCentralCrossRef
102.
Sionov RV, Gallily R (1990) Engulfment and intracellular killing of F9 teratocarcinoma cells by non-activated murine macrophages. Int Immunol 2(4):291–301PubMedCrossRef
103.
104.
Khayrullina T, Yen JH, Jing H, Ganea D (2008) In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells. J Immunol 181(1):721–735PubMedPubMedCentralCrossRef
105.
Lemos HP, Grespan R, Vieira SM, Cunha TM, Verri WA Jr, Fernandes KS, Souto FO, McInnes IB, Ferreira SH, Liew FY, Cunha FQ (2009) Prostaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNgamma production. Proc Natl Acad Sci U S A 106(14):5954–5959. doi:10.​1073/​pnas.​0812782106 PubMedPubMedCentralCrossRef
106.
107.
Yu Y, Chadee K (1998) Prostaglandin E2 stimulates IL-8 gene expression in human colonic epithelial cells by a posttranscriptional mechanism. J Immunol 161(7):3746–3752PubMed
108.
109.
Weller CL, Collington SJ, Hartnell A, Conroy DM, Kaise T, Barker JE, Wilson MS, Taylor GW, Jose PJ, Williams TJ (2007) Chemotactic action of prostaglandin E2 on mouse mast cells acting via the PGE2 receptor 3. Proc Natl Acad Sci U S A 104(28):11712–11717. doi:10.​1073/​pnas.​0701700104 PubMedPubMedCentralCrossRef
110.
Aso H, Ito S, Mori A, Morioka M, Suganuma N, Kondo M, Imaizumi K, Hasegawa Y (2012) Prostaglandin E2 enhances interleukin-8 production via EP4 receptor in human pulmonary microvascular endothelial cells. Am J Physiol Lung Cell Mol Physiol 302(2):L266–L273. doi:10.​1152/​ajplung.​00248.​2011 PubMedCrossRef
111.
He LK, Liu LH, Hahn E, Gamelli RL (2001) The expression of cyclooxygenase and the production of prostaglandin E2 in neutrophils after burn injury and infection. J Burn Care Rehabil 22(1):58–64PubMedCrossRef
112.
113.
Ottonello L, Gonella R, Dapino P, Sacchetti C, Dallegri F (1998) Prostaglandin E2 inhibits apoptosis in human neutrophilic polymorphonuclear leukocytes: role of intracellular cyclic AMP levels. Exp Hematol 26(9):895–902PubMed
114.
115.
Ham EA, Soderman DD, Zanetti ME, Dougherty HW, McCauley E, Kuehl FA Jr (1983) Inhibition by prostaglandins of leukotriene B4 release from activated neutrophils. Proc Natl Acad Sci U S A 80(14):4349–4353PubMedPubMedCentralCrossRef
116.
Talpain E, Armstrong RA, Coleman RA, Vardey CJ (1995) Characterization of the PGE receptor subtype mediating inhibition of superoxide production in human neutrophils. Br J Pharmacol 114(7):1459–1465PubMedPubMedCentralCrossRef
117.
Ottonello L, Morone MP, Dapino P, Dallegri F (1995) Cyclic AMP-elevating agents down-regulate the oxidative burst induced by granulocyte-macrophage colony-stimulating factor (GM-CSF) in adherent neutrophils. Clin Exp Immunol 101(3):502–506PubMedPubMedCentralCrossRef
118.
Yu CL, Huang MH, Kung YY, Tsai CY, Tsai YY, Tsai ST, Huang DF, Sun KH, Han SH, Yu HS (1998) Interleukin-13 increases prostaglandin E2 (PGE2) production by normal human polymorphonuclear neutrophils by enhancing cyclooxygenase 2 (COX-2) gene expression. Inflamm Res 47(4):167–173PubMedCrossRef
119.
Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L, Kronenberg M, Miller PW, Portanova J, Lee JC, Dubinett SM (2000) Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164(1):361–370PubMedCrossRef
120.
121.
Dominguez-Luis M, Herrera-Garcia A, Arce-Franco M, Armas-Gonzalez E, Rodriguez-Pardo M, Lorenzo-Diaz F, Feria M, Cadenas S, Sanchez-Madrid F, Diaz-Gonzalez F (2013) Superoxide anion mediates the L-selectin down-regulation induced by non-steroidal anti-inflammatory drugs in human neutrophils. Biochem Pharmacol 85(2):245–256. doi:10.​1016/​j.​bcp.​2012.​10.​024 PubMedCrossRef
122.
Baratelli F, Lee JM, Hazra S, Lin Y, Walser TC, Schaue D, Pak PS, Elashoff D, Reckamp K, Zhang L, Fishbein MC, Sharma S, Dubinett SM (2010) PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer. Am J Transl Res 2(4):356–367PubMedPubMedCentral
123.
124.
125.
Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, Mack M, Pipeleers D, In’t Veld P, De Baetselier P, Van Ginderachter JA (2010) Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 70(14):5728–5739. doi:10.​1158/​0008-5472.​CAN-09-4672 PubMedCrossRef
126.
Yu J, Du W, Yan F, Wang Y, Li H, Cao S, Yu W, Shen C, Liu J, Ren X (2013) Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 190(7):3783–3797. doi:10.​4049/​jimmunol.​1201449 PubMedCrossRef
127.
128.
129.
Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204(6):1257–1265. doi:10.​1084/​jem.​20062512 PubMedPubMedCentralCrossRef
130.
131.
132.
133.
134.
Reutershan J, Vollmer I, Stark S, Wagner R, Ngamsri KC, Eltzschig HK (2009) Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J 23(2):473–482. doi:10.​1096/​fj.​08-119701 PubMedCrossRef
135.
136.
137.
Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166(1):678–689PubMedCrossRef
138.
139.
140.
141.
Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K (2009) Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 58(1):15–23. doi:10.​1007/​s00262-008-0516-3 PubMedCrossRef
142.
Choi J, Suh B, Ahn YO, Kim TM, Lee JO, Lee SH, Heo DS (2012) CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function. Tumour Biol 33(1):121–129. doi:10.​1007/​s13277-011-0254-6 PubMedCrossRef
143.
144.
Demirtas A, Sabur V, Akinsal EC, Demirci D, Ekmekcioglu O, Gulmez I, Tatlisen A (2013) Can neutrophil-lymphocyte ratio and lymph node density be used as prognostic factors in patients undergoing radical cystectomy? ScientificWorldJournal 2013:703579. doi:10.​1155/​2013/​703579 PubMedPubMedCentralCrossRef
145.
Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, Wu XJ, Lu ZH, Lin JZ, Kong LH, Wan DS, Pan ZZ (2010) Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 25(12):1427–1433. doi:10.​1007/​s00384-010-1052-0 PubMedCrossRef
146.
147.
Eruslanov E, Neuberger M, Daurkin I, Perrin GQ, Algood C, Dahm P, Rosser C, Vieweg J, Gilbert SM, Kusmartsev S (2012) Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer 130(5):1109–1119. doi:10.​1002/​ijc.​26123 PubMedCrossRef
148.
Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, Prasad KR (2008) Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 32(8):1757–1762. doi:10.​1007/​s00268-008-9552-6 PubMedCrossRef
149.
Gondo T, Nakashima J, Ohno Y, Choichiro O, Horiguchi Y, Namiki K, Yoshioka K, Ohori M, Hatano T, Tachibana M (2012) Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology 79(5):1085–1091. doi:10.​1016/​j.​urology.​2011.​11.​070 PubMedCrossRef
150.
Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ, Lodge JP (2008) Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol 34(1):55–60. doi:10.​1016/​j.​ejso.​2007.​02.​014 PubMedCrossRef
151.
152.
Liu H, Liu G, Bao Q, Sun W, Bao H, Bi L, Wen W, Liu Y, Wang Z, Yin X, Bai Y, Hu X (2010) The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in rectal carcinoma. J Gastrointest Cancer 41(2):116–120. doi:10.​1007/​s12029-009-9125-4 PubMedCrossRef
153.
154.
155.
Sato T, Omura M, Saito J, Hirasawa A, Kakuta Y, Wakabayashi Y, Nishikawa T (2000) Neutrophilia associated with anaplastic carcinoma of the thyroid: production of macrophage colony-stimulating factor (M-CSF) and interleukin-6. Thyroid 10(12):1113–1118PubMedCrossRef
156.
Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keilholz U (2007) Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol 25(12):1562–1569. doi:10.​1200/​JCO.​2006.​09.​0274 PubMedCrossRef
157.
Trellakis S, Bruderek K, Dumitru CA, Gholaman H, Gu X, Bankfalvi A, Scherag A, Hutte J, Dominas N, Lehnerdt GF, Hoffmann TK, Lang S, Brandau S (2011) Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. Int J Cancer 129(9):2183–2193. doi:10.​1002/​ijc.​25892 PubMedCrossRef
158.
159.
Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M (2007) The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 73(3–4):215–220. doi:10.​1159/​000127412 PubMedCrossRef
160.
Melani C, Chiodoni C, Forni G, Colombo MP (2003) Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102(6):2138–2145. doi:10.​1182/​blood-2003-01-0190 PubMedCrossRef
161.
162.
Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, Gabrilovich D (2003) All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 63(15):4441–4449PubMed
163.
Liu H, Tabuchi T, Takemura A, Kasuga T, Motohashi G, Hiraishi K, Katano M, Nakada I, Ubukata H (2008) The granulocyte/lymphocyte ratio as an independent predictor of tumour growth, metastasis and progression: its clinical applications. Mol Med Rep 1(5):699–704. doi:10.​3892/​mmr_​00000016 PubMed
164.
Aeed PA, Nakajima M, Welch DR (1988) The role of polymorphonuclear leukocytes (PMN) on the growth and metastatic potential of 13762NF mammary adenocarcinoma cells. Int J Cancer 42(5):748–759PubMedCrossRef
165.
McGary CT, Miele ME, Welch DR (1995) Highly metastatic 13762NF rat mammary adenocarcinoma cell clones stimulate bone marrow by secretion of granulocyte-macrophage colony-stimulating factor/interleukin-3 activity. Am J Pathol 147(6):1668–1681PubMedPubMedCentral
166.
Welch DR, Schissel DJ, Howrey RP, Aeed PA (1989) Tumor-elicited polymorphonuclear cells, in contrast to “normal” circulating polymorphonuclear cells, stimulate invasive and metastatic potentials of rat mammary adenocarcinoma cells. Proc Natl Acad Sci U S A 86(15):5859–5863PubMedPubMedCentralCrossRef
167.
168.
Schaider H, Oka M, Bogenrieder T, Nesbit M, Satyamoorthy K, Berking C, Matsushima K, Herlyn M (2003) Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer 103(3):335–343. doi:10.​1002/​ijc.​10775 PubMedCrossRef
169.
Lee LF, Hellendall RP, Wang Y, Haskill JS, Mukaida N, Matsushima K, Ting JP (2000) IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol 164(5):2769–2775PubMedCrossRef
170.
Bellocq A, Antoine M, Flahault A, Philippe C, Crestani B, Bernaudin JF, Mayaud C, Milleron B, Baud L, Cadranel J (1998) Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. Am J Pathol 152(1):83–92PubMedPubMedCentral
171.
Gijsbers K, Gouwy M, Struyf S, Wuyts A, Proost P, Opdenakker G, Penninckx F, Ectors N, Geboes K, Van Damme J (2005) GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors. Exp Cell Res 303(2):331–342. doi:10.​1016/​j.​yexcr.​2004.​09.​027 PubMedCrossRef
172.
Asano Y, Yokoyama T, Shibata S, Kobayashi S, Shimoda K, Nakashima H, Okamura S, Niho Y (1997) Effect of the chimeric soluble granulocyte colony-stimulating factor receptor on the proliferation of leukemic blast cells from patients with acute myeloblastic leukemia. Cancer Res 57(16):3395–3397PubMed
173.
174.
Joshita S, Nakazawa K, Sugiyama Y, Kamijo A, Matsubayashi K, Miyabayashi H, Furuta K, Kitano K, Kawa S (2009) Granulocyte-colony stimulating factor-producing pancreatic adenosquamous carcinoma showing aggressive clinical course. Intern Med 48(9):687–691PubMedCrossRef
175.
176.
Savarese TM, Mitchell K, McQuain C, Campbell CL, Guardiani R, Wuu J, Ollari C, Reale F, Nelson BE, Chen A, Quesenberry PJ (2001) Coexpression of granulocyte colony stimulating factor and its receptor in primary ovarian carcinomas. Cancer Lett 162(1):105–115PubMedCrossRef
177.
Tsukuda M, Nagahara T, Yago T, Matsuda H, Yanoma S (1993) Production of granulocyte colony-stimulating factor by head and neck carcinomas. Biotherapy 6(3):183–187PubMedCrossRef
178.
179.
180.
Urdinguio RG, Fernandez AF, Moncada-Pazos A, Huidobro C, Rodriguez RM, Ferrero C, Martinez-Camblor P, Obaya AJ, Bernal T, Parra-Blanco A, Rodrigo L, Santacana M, Matias-Guiu X, Soldevilla B, Dominguez G, Bonilla F, Cal S, Lopez-Otin C, Fraga MF (2013) Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors. Cancer Res 73(1):395–405. doi:10.​1158/​0008-5472.​CAN-12-0806 PubMedCrossRef
181.
Braun B, Lange M, Oeckler R, Mueller MM (2004) Expression of G-CSF and GM-CSF in human meningiomas correlates with increased tumor proliferation and vascularization. J Neurooncol 68(2):131–140PubMedCrossRef
182.
183.
Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25(18):2546–2553. doi:10.​1200/​JCO.​2006.​08.​5829 PubMedCrossRef
184.
Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, Restifo NP (1999) Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 162(10):5728–5737PubMedPubMedCentral
185.
Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I (2004) High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 64(17):6337–6343. doi:10.​1158/​0008-5472.​CAN-04-0757 PubMedCrossRef
186.
Fu YX, Watson G, Jimenez JJ, Wang Y, Lopez DM (1990) Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor. Cancer Res 50(2):227–234PubMed
187.
Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90(8):3539–3543PubMedPubMedCentralCrossRef
188.
Avalos BR, Gasson JC, Hedvat C, Quan SG, Baldwin GC, Weisbart RH, Williams RE, Golde DW, DiPersio JF (1990) Human granulocyte colony-stimulating factor: biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines. Blood 75(4):851–857PubMed
189.
Kobashi Y, Okimoto N, Sakamoto K (2004) Squamous cell carcinoma of the lung producing granulocyte colony-stimulating factor and resembling a malignant pleural mesothelioma. Intern Med 43(2):111–116PubMedCrossRef
190.
Hsu DM, Agarwal S, Benham A, Coarfa C, Trahan DN, Chen Z, Stowers PN, Courtney AN, Lakoma A, Barbieri E, Metelitsa LS, Gunaratne P, Kim ES, Shohet JM (2013) G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res 73(13):4134–4146. doi:10.​1158/​0008-5472.​CAN-12-4056 PubMedPubMedCentralCrossRef
191.
192.
193.
194.
Tachibana M, Murai M (1998) G-CSF production in human bladder cancer and its ability to promote autocrine growth: a review. Cytokines Cell Mol Ther 4(2):113–120PubMed
195.
Tachibana M, Miyakawa A, Uchida A, Murai M, Eguchi K, Nakamura K, Kubo A, Hata JI (1997) Granulocyte colony-stimulating factor receptor expression on human transitional cell carcinoma of the bladder. Br J Cancer 75(10):1489–1496PubMedPubMedCentralCrossRef
196.
Ninci EB, Brandstetter T, Meinhold-Heerlein I, Bettendorf H, Sellin D, Bauknecht T (2000) G-CSF receptor expression in ovarian cancer. Int J Gynecol Cancer 10(1):19–26PubMedCrossRef
197.
198.
Morales-Arias J, Meyers PA, Bolontrade MF, Rodriguez N, Zhou Z, Reddy K, Chou AJ, Koshkina NV, Kleinerman ES (2007) Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration. Cancer 110(7):1568–1577. doi:10.​1002/​cncr.​22964 PubMedCrossRef
199.
200.
201.
Griffiths AP, Rice A, Dixon MF (1998) Anaplastic gastric adenocarcinoma with extensive neutrophilic infiltration. Histopathology 33(4):392–393PubMedCrossRef
202.
Rice AJ, Griffiths AP, Martin IG, Dixon MF (2000) Gastric carcinoma with prominent neutrophil infiltration. Histopathology 37(3):289–290PubMedCrossRef
203.
Wislez M, Rabbe N, Marchal J, Milleron B, Crestani B, Mayaud C, Antoine M, Soler P, Cadranel J (2003) Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. Cancer Res 63(6):1405–1412PubMed
204.
Ilie M, Hofman V, Ortholan C, Bonnetaud C, Coelle C, Mouroux J, Hofman P (2012) Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer 118(6):1726–1737. doi:10.​1002/​cncr.​26456 PubMedCrossRef
205.
206.
Gaida MM, Steffen TG, Gunther F, Tschaharganeh DF, Felix K, Bergmann F, Schirmacher P, Hansch GM (2012) Polymorphonuclear neutrophils promote dyshesion of tumor cells and elastase-mediated degradation of E-cadherin in pancreatic tumors. Eur J Immunol 42(12):3369–3380. doi:10.​1002/​eji.​201242628 PubMedCrossRef
207.
Fossati G, Ricevuti G, Edwards SW, Walker C, Dalton A, Rossi ML (1999) Neutrophil infiltration into human gliomas. Acta Neuropathol 98(4):349–354PubMedCrossRef
208.
209.
210.
211.
212.
Wuyts A, Proost P, Lenaerts JP, Ben-Baruch A, Van Damme J, Wang JM (1998) Differential usage of the CXC chemokine receptors 1 and 2 by interleukin-8, granulocyte chemotactic protein-2 and epithelial-cell-derived neutrophil attractant-78. Eur J Biochem 255(1):67–73PubMedCrossRef
213.
Ahuja SK, Murphy PM (1996) The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J Biol Chem 271(34):20545–20550PubMedCrossRef
214.
Song J, Wu C, Zhang X, Sorokin LM (2013) In vivo processing of CXCL5 (LIX) by matrix metalloproteinase (MMP)-2 and MMP-9 promotes early neutrophil recruitment in IL-1beta-induced peritonitis. J Immunol 190(1):401–410. doi:10.​4049/​jimmunol.​1202286 PubMedCrossRef
215.
Schenk BI, Petersen F, Flad HD, Brandt E (2002) Platelet-derived chemokines CXC chemokine ligand (CXCL)7, connective tissue-activating peptide III, and CXCL4 differentially affect and cross-regulate neutrophil adhesion and transendothelial migration. J Immunol 169(5):2602–2610PubMedCrossRef
216.
Bru A, Souto JC, Alcolea S, Anton R, Remacha A, Camacho M, Soler M, Bru I, Porres A, Vila L (2009) Tumour cell lines HT-29 and FaDu produce proinflammatory cytokines and activate neutrophils in vitro: possible applications for neutrophil-based antitumour treatment. Mediators Inflamm 2009:817498. doi:10.​1155/​2009/​817498 PubMedPubMedCentralCrossRef
217.
Yamashiro S, Kamohara H, Wang JM, Yang D, Gong WH, Yoshimura T (2001) Phenotypic and functional change of cytokine-activated neutrophils: inflammatory neutrophils are heterogeneous and enhance adaptive immune responses. J Leukoc Biol 69(5):698–704PubMed
218.
219.
Jamieson T, Clarke M, Steele CW, Samuel MS, Neumann J, Jung A, Huels D, Olson MF, Das S, Nibbs RJ, Sansom OJ (2012) Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Invest 122(9):3127–3144. doi:10.​1172/​JCI61067 PubMedPubMedCentralCrossRef
220.
221.
222.
Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7(11):1194–1201. doi:10.​1038/​nm1101-1194 PubMedCrossRef
223.
Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, Chimenti S, Landsman L, Abramovitch R, Keshet E (2006) VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124(1):175–189. doi:10.​1016/​j.​cell.​2005.​10.​036 PubMedCrossRef
224.
225.
Ji YN, Wang Q, Li Y, Wang Z (2013) Prognostic value of vascular endothelial growth factor A expression in gastric cancer: a meta-analysis. Tumour Biol. doi:10.​1007/​s13277-013-1371-1
226.
Minardi D, Lucarini G, Santoni M, Mazzucchelli R, Burattini L, Pistelli M, Bianconi M, Di Primio R, Scartozzi M, Montironi R, Cascinu S, Muzzonigro G (2013) VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma. Anticancer Res 33(11):5017–5022PubMed
227.
228.
Salmaggi A, Gelati M, Pollo B, Frigerio S, Eoli M, Silvani A, Broggi G, Ciusani E, Croci D, Boiardi A, De Rossi M (2004) CXCL12 in malignant glial tumors: a possible role in angiogenesis and cross-talk between endothelial and tumoral cells. J Neurooncol 67(3):305–317PubMedCrossRef
229.
Santiago B, Calonge E, Del Rey MJ, Gutierrez-Canas I, Izquierdo E, Usategui A, Galindo M, Alcami J, Pablos JL (2011) CXCL12 gene expression is upregulated by hypoxia and growth arrest but not by inflammatory cytokines in rheumatoid synovial fibroblasts. Cytokine 53(2):184–190. doi:10.​1016/​j.​cyto.​2010.​06.​006 PubMedCrossRef
230.
Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, Moons L, Wei S, Zou L, Machelon V, Emilie D, Terrassa M, Lackner A, Curiel TJ, Carmeliet P, Zou W (2005) CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 65(2):465–472PubMed
231.
Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV, Ouyang W, Ferrara N (2013) An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med. doi:10.​1038/​nm.​3291
232.
233.
234.
235.
Bailey C, Negus R, Morris A, Ziprin P, Goldin R, Allavena P, Peck D, Darzi A (2007) Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin Exp Metastasis 24(2):121–130. doi:10.​1007/​s10585-007-9060-3 PubMedCrossRef
236.
237.
Tanaka K, Kurebayashi J, Sohda M, Nomura T, Prabhakar U, Yan L, Sonoo H (2009) The expression of monocyte chemotactic protein-1 in papillary thyroid carcinoma is correlated with lymph node metastasis and tumor recurrence. Thyroid 19(1):21–25. doi:10.​1089/​thy.​2008.​0237 PubMedCrossRef
238.
Yoshidome H, Kohno H, Shida T, Kimura F, Shimizu H, Ohtsuka M, Nakatani Y, Miyazaki M (2009) Significance of monocyte chemoattractant protein-1 in angiogenesis and survival in colorectal liver metastases. Int J Oncol 34(4):923–930PubMedCrossRef
239.
Zijlmans HJ, Fleuren GJ, Baelde HJ, Eilers PH, Kenter GG, Gorter A (2006) The absence of CCL2 expression in cervical carcinoma is associated with increased survival and loss of heterozygosity at 17q11.2. J Pathol 208(4):507–517. doi:10.​1002/​path.​1918 PubMedCrossRef
240.
241.
242.
Nakashima E, Mukaida N, Kubota Y, Kuno K, Yasumoto K, Ichimura F, Nakanishi I, Miyasaka M, Matsushima K (1995) Human MCAF gene transfer enhances the metastatic capacity of a mouse cachectic adenocarcinoma cell line in vivo. Pharm Res 12(11):1598–1604PubMedCrossRef
243.
244.
Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, Wojno K, Snyder LA, Yan L, Pienta KJ (2007) Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 67(19):9417–9424PubMedCrossRef
245.
Yang EJ, Choi E, Ko J, Kim DH, Lee JS, Kim IS (2012) Differential effect of CCL2 on constitutive neutrophil apoptosis between normal and asthmatic subjects. J Cell Physiol 227(6):2567–2577. doi:10.​1002/​jcp.​22995 PubMedCrossRef
246.
Bolitho C, Hahn MA, Baxter RC, Marsh DJ (2010) The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Endocr Relat Cancer 17(4):929–940. doi:10.​1677/​ERC-10-0107 PubMedCrossRef
247.
Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D et al (1995) The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270(45):27348–27357PubMedCrossRef
248.
Kuo PL, Shen KH, Hung SH, Hsu YL (2012) CXCL1/GROalpha increases cell migration and invasion of prostate cancer by decreasing fibulin-1 expression through NF-kappaB/HDAC1 epigenetic regulation. Carcinogenesis 33(12):2477–2487. doi:10.​1093/​carcin/​bgs299 PubMedCrossRef
249.
Scapini P, Morini M, Tecchio C, Minghelli S, Di Carlo E, Tanghetti E, Albini A, Lowell C, Berton G, Noonan DM, Cassatella MA (2004) CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. J Immunol 172(8):5034–5040PubMedCrossRef
250.
Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, Norton L, Brogi E, Massague J (2012) A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150(1):165–178PubMedPubMedCentralCrossRef
251.
252.
253.
254.
255.
256.
257.
Haqqani AS, Sandhu JK, Birnboim HC (2000) Expression of interleukin-8 promotes neutrophil infiltration and genetic instability in mutatect tumors. Neoplasia 2(6):561–568PubMedPubMedCentralCrossRef
258.
259.
260.
261.
262.
Ginzberg HH, Cherapanov V, Dong Q, Cantin A, McCulloch CA, Shannon PT, Downey GP (2001) Neutrophil-mediated epithelial injury during transmigration: role of elastase. Am J Physiol Gastrointest Liver Physiol 281(3):G705–G717PubMed
263.
Grosse-Steffen T, Giese T, Giese N, Longerich T, Schirmacher P, Hansch GM, Gaida MM (2012) Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma and pancreatic tumor cell lines: the role of neutrophils and neutrophil-derived elastase. Clin Dev Immunol 2012:720768. doi:10.​1155/​2012/​720768 PubMedPubMedCentralCrossRef
264.
Pekarek LA, Starr BA, Toledano AY, Schreiber H (1995) Inhibition of tumor growth by elimination of granulocytes. J Exp Med 181(1):435–440PubMedCrossRef
265.
Tazawa H, Okada F, Kobayashi T, Tada M, Mori Y, Une Y, Sendo F, Kobayashi M, Hosokawa M (2003) Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. Am J Pathol 163(6):2221–2232. doi:10.​1016/​S0002-9440(10)63580-8 PubMedPubMedCentralCrossRef
266.
267.
Balbin M, Fueyo A, Tester AM, Pendas AM, Pitiot AS, Astudillo A, Overall CM, Shapiro SD, Lopez-Otin C (2003) Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 35(3):252–257. doi:10.​1038/​ng1249 PubMedCrossRef
268.
Bodey B, Bodey B Jr, Siegel SE, Luck JV, Kaiser HE (1996) Immunophenotypic characterization of human primary and metastatic melanoma infiltrating leukocytes. Anticancer Res 16(6B):3439–3446PubMed
269.
Yu J, Ren X, Chen Y, Liu P, Wei X, Li H, Ying G, Chen K, Winkler H, Hao X (2013) Dysfunctional activation of neurotensin/IL-8 pathway in hepatocellular carcinoma is associated with increased inflammatory response in microenvironment, more epithelial mesenchymal transition in cancer and worse prognosis in patients. PLoS One 8(2):e56069. doi:10.​1371/​journal.​pone.​0056069 PubMedPubMedCentralCrossRef
270.
271.
272.
273.
Anderson IC, Mari SE, Broderick RJ, Mari BP, Shipp MA (2000) The angiogenic factor interleukin 8 is induced in non-small cell lung cancer/pulmonary fibroblast cocultures. Cancer Res 60(2):269–272PubMed
274.
Chen JJ, Yao PL, Yuan A, Hong TM, Shun CT, Kuo ML, Lee YC, Yang PC (2003) Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 9(2):729–737PubMed
275.
276.
Yamano T, Morii E, Ikeda J, Aozasa K (2007) Granulocyte colony-stimulating factor production and rapid progression of gastric cancer after histological change in the tumor. Jpn J Clin Oncol 37(10):793–796. doi:10.​1093/​jjco/​hym094 PubMedCrossRef
277.
278.
Schmielau J, Finn OJ (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 61(12):4756–4760PubMed
279.
Okazaki T, Ebihara S, Asada M, Kanda A, Sasaki H, Yamaya M (2006) Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int Immunol 18(1):1–9. doi:10.​1093/​intimm/​dxh334 PubMedCrossRef
280.
Natori T, Sata M, Washida M, Hirata Y, Nagai R, Makuuchi M (2002) G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun 297(4):1058–1061PubMedCrossRef
281.
282.
283.
Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N, Ho C, Ross J, Tan M, Carano RA, Meng YG, Ferrara N (2007) Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450(7171):825–831. doi:10.​1038/​nature06348 PubMedCrossRef
284.
285.
Ohki Y, Heissig B, Sato Y, Akiyama H, Zhu Z, Hicklin DJ, Shimada K, Ogawa H, Daida H, Hattori K, Ohsaka A (2005) Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils. FASEB J 19(14):2005–2007. doi:10.​1096/​fj.​04-3496fje PubMed
286.
Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2(10):737–744. doi:10.​1038/​35036374 PubMedPubMedCentralCrossRef
287.
288.
Imai Y, Kubota Y, Yamamoto S, Tsuji K, Shimatani M, Shibatani N, Takamido S, Matsushita M, Okazaki K (2005) Neutrophils enhance invasion activity of human cholangiocellular carcinoma and hepatocellular carcinoma cells: an in vitro study. J Gastroenterol Hepatol 20(2):287–293. doi:10.​1111/​j.​1440-1746.​2004.​03575.​x PubMedCrossRef
289.
Di Carlo E, Forni G, Musiani P (2003) Neutrophils in the antitumoral immune response. Chem Immunol Allergy 83:182–203PubMedCrossRef
290.
Shamamian P, Schwartz JD, Pocock BJ, Monea S, Whiting D, Marcus SG, Mignatti P (2001) Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 189(2):197–206. doi:10.​1002/​jcp.​10014 PubMedCrossRef
291.
292.
293.
294.
295.
296.
Wu QD, Wang JH, Condron C, Bouchier-Hayes D, Redmond HP (2001) Human neutrophils facilitate tumor cell transendothelial migration. Am J Physiol Cell Physiol 280(4):C814–C822PubMed
297.
Jadhav S, Bochner BS, Konstantopoulos K (2001) Hydrodynamic shear regulates the kinetics and receptor specificity of polymorphonuclear leukocyte-colon carcinoma cell adhesive interactions. J Immunol 167(10):5986–5993PubMedCrossRef
298.
299.
Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM, Shibuya M (2002) MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2(4):289–300PubMedCrossRef
300.
Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438(7069):820–827PubMedPubMedCentralCrossRef
301.
Hiratsuka S, Watanabe A, Aburatani H, Maru Y (2006) Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8(12):1369–1375PubMedCrossRef
302.
303.
Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R, Sadik H, Argani P, Wagner P, Vahdat LT, Port JL, Stiles B, Sukumar S, Altorki NK, Rafii S, Mittal V (2012) Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res 72(6):1384–1394PubMedCrossRef
304.
Sceneay J, Chow MT, Chen A, Halse HM, Wong CS, Andrews DM, Sloan EK, Parker BS, Bowtell DD, Smyth MJ, Moller A (2012) Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res 72(16):3906–3911. doi:10.​1158/​0008-5472.​CAN-11-3873 PubMedCrossRef
305.
306.
Cools-Lartigue J, Spicer J, McDonald B, Gowing S, Chow S, Giannias B, Bourdeau F, Kubes P, Ferri L (2013) Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. doi:10.​1172/​JCI67484 PubMedPubMedCentral
307.
308.
Bubenik J, Perlmann P, Helmstein K, Moberger G (1970) Cellular and humoral immune responses to human urinary bladder carcinomas. Int J Cancer 5(3):310–319PubMedCrossRef
309.
Shau H (1988) Cytostatic and tumoricidal activities of tumor necrosis factor-treated neutrophils. Immunol Lett 17(1):47–51PubMedCrossRef
310.
Shau H (1988) Characteristics and mechanism of neutrophil-mediated cytostasis induced by tumor necrosis factor. J Immunol 141(1):234–240PubMed
311.
Miyake Y, Ajitsu S, Yamashita T, Sendo F (1988) Enhancement by recombinant interferon-gamma of spontaneous tumor cytostasis by human neutrophils. Mol Biother 1(1):37–42PubMed
312.
313.
314.
Slivka A, LoBuglio AF, Weiss SJ (1980) A potential role for hypochlorous acid in granulocyte-mediated tumor cell cytotoxicity. Blood 55(2):347–350PubMed
315.
Clark RA, Klebanoff SJ (1979) Role of the myeloperoxidase-H2O2-halide system in concanavalin A-induced tumor cell killing by human neutrophils. J Immunol 122(6):2605–2610PubMed
316.
Weiss SJ, Slivka A (1982) Monocyte and granulocyte-mediated tumor cell destruction. A role for the hydrogen peroxide-myeloperoxidase-chloride system. J Clin Invest 69(2):255–262PubMedPubMedCentralCrossRef
317.
Dallegri F, Frumento G, Patrone F (1983) Mechanisms of tumour cell destruction by PMA-activated human neutrophils. Immunology 48(2):273–279PubMedPubMedCentral
318.
Abrams SI, Brahmi Z (1984) Compared mechanisms of tumor cytolysis by human natural killer cells and activated polymorphonuclear leukocytes. J Immunol 132(6):3192–3196PubMed
319.
Bru A, Albertos S, Lopez Garcia-Asenjo JA, Bru I (2004) Pinning of tumoral growth by enhancement of the immune response. Phys Rev Lett 92(23):238101PubMedCrossRef
320.
Su YB, Vickers AJ, Zelefsky MJ, Kraus DH, Shaha AR, Shah JP, Serio AM, Harrison LB, Bosl GJ, Pfister DG (2006) Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer. Cancer J 12(3):182–188PubMedCrossRef
321.
Rini BI, Fong L, Weinberg V, Kavanaugh B, Small EJ (2006) Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. J Urol 175(6):2087–2091. doi:10.​1016/​S0022-5347(06)00261-8 PubMedCrossRef
322.
Bottoni U, Bonaccorsi P, Devirgiliis V, Panasiti V, Borroni RG, Trasimeni G, Clerico R, Calvieri S (2005) Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF. Jpn J Clin Oncol 35(9):507–513. doi:10.​1093/​jjco/​hyi141 PubMedCrossRef
323.
324.
325.
Dissemond J, Weimann TK, Schneider LA, Schneeberger A, Scharffetter-Kochanek K, Goos M, Wagner SN (2003) Activated neutrophils exert antitumor activity against human melanoma cells: reactive oxygen species-induced mechanisms and their modulation by granulocyte-macrophage-colony-stimulating factor. J Invest Dermatol 121(4):936–938. doi:10.​1046/​j.​1523-1747.​2003.​12475.​x PubMedCrossRef
326.
Zivkovic M, Poljak-Blazi M, Egger G, Sunjic SB, Schaur RJ, Zarkovic N (2005) Oxidative burst and anticancer activities of rat neutrophils. Biofactors 24(1–4):305–312PubMedCrossRef
327.
Clark RA, Klebanoff SJ (1975) Neutrophil-mediated tumor cell cytotoxicity: role of the peroxidase system. J Exp Med 141(6):1442–1447PubMedCrossRef
328.
Lichtenstein A, Kahle J (1985) Anti-tumor effect of inflammatory neutrophils: characteristics of in vivo generation and in vitro tumor cell lysis. Int J Cancer 35(1):121–127PubMedCrossRef
329.
Caruso RA, Speciale G, Inferrera C (1994) Neutrophil interaction with tumour cells in small early gastric cancer: ultrastructural observations. Histol Histopathol 9(2):295–303PubMed
330.
Saito H, Fukumura D, Kurose I, Suematsu M, Tada S, Kagawa T, Miura S, Morizane T, Tsuchiya M (1992) Visualization of oxidative processes at the cellular level during neutrophil-mediated cytotoxicity against a human hepatoma cell line, HCC-M. Int J Cancer 51(1):124–129PubMedCrossRef
331.
Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P (2001) The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97(2):339–345PubMedCrossRef
332.
Yamazaki M, Ikenami M, Sugiyama T (1988) Cytolytic heterogeneity of polymorphonuclear leukocytes in killing of murine tumor cells. Jpn J Cancer Res 79(11):1217–1223PubMedCrossRef
333.
Koga Y, Matsuzaki A, Suminoe A, Hattori H, Hara T (2004) Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): a novel mechanism of antitumor effect by neutrophils. Cancer Res 64(3):1037–1043PubMedCrossRef
334.
335.
Lichtenstein A, Ganz T, Selsted ME, Lehrer RI (1986) In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. Blood 68(6):1407–1410PubMed
336.
Kushner BH, Cheung NK (1992) Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity. Blood 79(6):1484–1490PubMed
337.
Iliopoulos D, Ernst C, Steplewski Z, Jambrosic JA, Rodeck U, Herlyn M, Clark WH Jr, Koprowski H, Herlyn D (1989) Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst 81(6):440–444PubMedCrossRef
338.
Valerius T, Repp R, de Wit TP, Berthold S, Platzer E, Kalden JR, Gramatzki M, van de Winkel JG (1993) Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 82(3):931–939PubMed
339.
340.
341.
Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS (2003) Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin’s lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 9(16 Pt 1):5866–5873PubMed
342.
Hubert P, Heitzmann A, Viel S, Nicolas A, Sastre-Garau X, Oppezzo P, Pritsch O, Osinaga E, Amigorena S (2011) Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer Res 71(15):5134–5143. doi:10.​1158/​0008-5472.​CAN-10-4222 PubMedCrossRef
343.
Guettinger Y, Barbin K, Peipp M, Bruenke J, Dechant M, Horner H, Thierschmidt D, Valerius T, Repp R, Fey GH, Stockmeyer B (2010) A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells. J Immunol 184(3):1210–1217. doi:10.​4049/​jimmunol.​0902033 PubMedCrossRef
344.
Stockmeyer B, Dechant M, van Egmond M, Tutt AL, Sundarapandiyan K, Graziano RF, Repp R, Kalden JR, Gramatzki M, Glennie MJ, van de Winkel JG, Valerius T (2000) Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J Immunol 165(10):5954–5961PubMedCrossRef
345.
Otten MA, Rudolph E, Dechant M, Tuk CW, Reijmers RM, Beelen RH, van de Winkel JG, van Egmond M (2005) Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J Immunol 174(9):5472–5480PubMedCrossRef
346.
347.
348.
Tanaka E, Sendo F (1993) Abrogation of tumor-inhibitory MRC-OX8+ (CD8+) effector T-cell generation in rats by selective depletion of neutrophils in vivo using a monoclonal antibody. Int J Cancer 54(1):131–136PubMedCrossRef
349.
350.
351.
Jackaman C, Lew AM, Zhan Y, Allan JE, Koloska B, Graham PT, Robinson BW, Nelson DJ (2008) Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol 20(11):1467–1479. doi:10.​1093/​intimm/​dxn104 PubMedCrossRef
352.
Takami K, Miura K, Takeuchi H, Egawa S, Moriya T, Nakamura Y, Tanabe A, Sugita J, Karasawa H, Unno M, Sasaki I (2008) Granulocyte-colony stimulating factor-producing pancreatic cancer: report of a case. Surg Today 38(5):453–457. doi:10.​1007/​s00595-007-3636-z PubMedCrossRef
353.
Fujiwara Y, Yamazaki O, Takatsuka S, Kaizaki R, Inoue T (2011) Granulocyte colony-stimulating factor-producing ascending colon cancer as indicated by histopathological findings: report of a case. Osaka City Med J 57(2):79–84PubMed
354.
355.
Matsuyama S, Shimonishi T, Yoshimura H, Higaki K, Nasu K, Toyooka M, Aoki S, Watanabe K, Sugihara H (2008) An autopsy case of granulocyte-colony-stimulating-factor-producing extrahepatic bile duct carcinoma. World J Gastroenterol 14(18):2924–2927PubMedPubMedCentralCrossRef
356.
Kawaguchi M, Asada Y, Terada T, Takehara A, Munemoto Y, Fujisawa K, Mitsui T, Iida Y, Miura S, Sudo Y (2010) Aggressive recurrence of gastric cancer as a granulocyte-colony-stimulating factor-producing tumor. Int J Clin Oncol 15(2):191–195. doi:10.​1007/​s10147-010-0023-3 PubMedCrossRef
357.
Ito S, Iwai Y, Fujii T, Yoshida N, Hayashi S (1999) Two cases of bladder tumor producing granulocyte colony stimulating factor. Hinyokika Kiyo 45(1):57–60PubMed
358.
359.
360.
Sakamoto A, Yamamoto H, Tanaka K, Matsuda S, Harimaya K, Oda Y, Tsuneyoshi M, Iwamoto Y (2006) Dedifferentiated chondrosarcoma with leukocytosis and elevation of serum G-CSF. A case report. World J Surg Oncol 4:37PubMedPubMedCentralCrossRef
361.
Sakamoto A, Matono H, Yoshida T, Tanaka K, Matsuda S, Oda Y, Iwamoto Y (2007) Dedifferentiated liposarcoma with leukocytosis. A case report of G-CSF-producing soft-tissue tumors, possible association with undifferentiated liposarcoma lineage. World J Surg Oncol 5:131PubMedPubMedCentralCrossRef
362.
Droeser RA, Hirt C, Eppenberger-Castori S, Zlobec I, Viehl CT, Frey DM, Nebiker CA, Rosso R, Zuber M, Amicarella F, Iezzi G, Sconocchia G, Heberer M, Lugli A, Tornillo L, Oertli D, Terracciano L, Spagnoli GC (2013) High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor. PLoS One 8(5):e64814. doi:10.​1371/​journal.​pone.​0064814 PubMedPubMedCentralCrossRef
363.
Hirt C, Eppenberger-Castori S, Sconocchia G, Iezzi G, Tornillo L, Terracciano L, Spagnoli GC, Droeser RA (2013) Colorectal carcinoma infiltration by myeloperoxidase-expressing neutrophil granulocytes is associated with favorable prognosis. Oncoimmunology 2(10):e25990. doi:10.​4161/​onci.​25990 PubMedPubMedCentralCrossRef
364.
Sconocchia G, Zlobec I, Lugli A, Calabrese D, Iezzi G, Karamitopoulou E, Patsouris ES, Peros G, Horcic M, Tornillo L, Zuber M, Droeser R, Muraro MG, Mengus C, Oertli D, Ferrone S, Terracciano L, Spagnoli GC (2011) Tumor infiltration by FcgammaRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer 128(11):2663–2672. doi:10.​1002/​ijc.​25609 PubMedPubMedCentralCrossRef
365.
366.
Riesco A (1970) Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer 25(1):135–140PubMedCrossRef
367.
368.
Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, Nakano K, Tsuboi M, Shibata K, Furuse K, Fukushima M (2009) Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 45(11):1950–1958. doi:10.​1016/​j.​ejca.​2009.​01.​023 PubMedCrossRef
369.
Ubukata H, Motohashi G, Tabuchi T, Nagata H, Konishi S (2010) Evaluations of interferon-gamma/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients. J Surg Oncol 102(7):742–747. doi:10.​1002/​jso.​21725 PubMedCrossRef
370.
371.
Wang GY, Yang Y, Zhang Q, Li H, Chen GZ, Yi SH, Xu C, Wang GS, Zhang J, Yi HM, Jiang N, Fu BS, Zhao H, Li MR, Chen YH, Cai CJ, Lu MQ, Chen GH (2011) Preoperative neutrophil-lymphocyte ratio as a prognostic predictor after liver transplantation for hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi 91(22):1519–1522PubMed
372.
Hung HY, Chen JS, Yeh CY, Changchien CR, Tang R, Hsieh PS, Tasi WS, You JF, You YT, Fan CW, Wang JY, Chiang JM (2011) Effect of preoperative neutrophil-lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. Int J Colorectal Dis 26(8):1059–1065. doi:10.​1007/​s00384-011-1192-x PubMedCrossRef
373.
Liu H, Ubukata H, Tabuchi T, Takemura A, Motohashi G, Nishimura M, Satani T, Hong J, Katano M, Nakada I, Saniabadi AR (2009) It is possible that tumour-infiltrating granulocytes promote tumour progression. Oncol Rep 22(1):29–33PubMed
374.
Trellakis S, Farjah H, Bruderek K, Dumitru CA, Hoffmann TK, Lang S, Brandau S (2011) Peripheral blood neutrophil granulocytes from patients with head and neck squamous cell carcinoma functionally differ from their counterparts in healthy donors. Int J Immunopathol Pharmacol 24(3):683–693PubMed
375.
376.
Dumitru CA, Gholaman H, Trellakis S, Bruderek K, Dominas N, Gu X, Bankfalvi A, Whiteside TL, Lang S, Brandau S (2011) Tumor-derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation. Int J Cancer 129(4):859–869. doi:10.​1002/​ijc.​25991 PubMedCrossRef
377.
378.
Ren Y, Tsui HT, Poon RT, Ng IO, Li Z, Chen Y, Jiang G, Lau C, Yu WC, Bacher M, Fan ST (2003) Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer 107(1):22–29. doi:10.​1002/​ijc.​11287 PubMedCrossRef
379.
Ren Y, Law S, Huang X, Lee PY, Bacher M, Srivastava G, Wong J (2005) Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann Surg 242(1):55–63PubMedPubMedCentralCrossRef
380.
381.
Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, Wang Z, Huang XW, Fan J, Zhou J (2012) Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology 56(6):2242–2254. doi:10.​1002/​hep.​25907 PubMedCrossRef
382.
Ietomi K (1990) A study on the role of granulocytes in carcinoma-bearing hosts–G/L ratio as a new host indicator. Nihon Gan Chiryo Gakkai Shi 25(3):662–671PubMed
383.
384.
Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI (2004) Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 172(2):989–999PubMedCrossRef
385.
Patel KD, Zimmerman GA, Prescott SM, McEver RP, McIntyre TM (1991) Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophils. J Cell Biol 112(4):749–759PubMedCrossRef
386.
Cherdyntseva NV, Bogdashin IV, Nebera SA, Vasil’ev NV (1989) Neutrophil granulocyte function in patients with malignant neoplasms. Vopr Onkol 35(4):429–433PubMed
387.
388.
Tsuda Y, Fukui H, Asai A, Fukunishi S, Miyaji K, Fujiwara S, Teramura K, Fukuda A, Higuchi K (2012) An immunosuppressive subtype of neutrophils identified in patients with hepatocellular carcinoma. J Clin Biochem Nutr 51(3):204–212. doi:10.​3164/​jcbn.​12-32 PubMedPubMedCentral
389.
Jensen TO, Schmidt H, Moller HJ, Donskov F, Hoyer M, Sjoegren P, Christensen IJ, Steiniche T (2012) Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 118(9):2476–2485. doi:10.​1002/​cncr.​26511 PubMedCrossRef
390.
Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H (2009) Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 27(28):4709–4717. doi:10.​1200/​JCO.​2008.​18.​9498 PubMedCrossRef
391.
392.
Chee DO, Townsend CM Jr, Galbraith MA, Eilber FR, Morton DL (1978) Selective reduction of human tumor cell populations by human granulocytes in vitro. Cancer Res 38(12):4534–4539PubMed
393.
Halbrecht I, Komlos L (1974) Cytotoxic effects of leukocytes and plasma on primary cultures of ovarian carcinoma. Obstet Gynecol 43(2):268–275PubMed
394.
Korec S, Herberman RB, Dean JH, Cannon GB (1980) Cytostasis of tumor cell lines by human granulocytes. Cell Immunol 53(1):104–115PubMedCrossRef
395.
Gerrard TL, Cohen DJ, Kaplan AM (1981) Human neutrophil-mediated cytotoxicity to tumor cells. J Natl Cancer Inst 66(3):483–488PubMed
396.
Cameron DJ (1983) A comparison of the cytotoxic potential in polymorphonuclear leukocytes obtained from normal donors and cancer patients. Clin Immunol Immunopathol 28(1):115–124PubMedCrossRef
397.
Cameron DJ (1986) Lidocaine inhibits macrophage mediated cytotoxicity and enhances neutrophil mediated cytotoxicity. Jpn J Exp Med 56(6):265–269PubMed
398.
Cameron DJ (1985) Inhibition of neutrophil-mediated cytotoxicity by exogenous adenosine 5′-triphosphate. Clin Immunol Immunopathol 37(2):230–235PubMedCrossRef
399.
Cameron DJ, Majeski JA (1988) Inhibition of macrophage- and neutrophil-mediated cytotoxicity by verapamil. J Surg Oncol 37(1):5–9PubMedCrossRef
400.
Cameron DJ (1986) Role of hydrocortisone, chloroquine and prednisolone in neutrophil mediated cytotoxicity. Jpn J Exp Med 56(5):207–212PubMed
401.
402.
Heidecke H, Eckert K, Schulze-Forster K, Maurer HR (1997) Prothymosin alpha 1 effects in vitro on chemotaxis, cytotoxicity and oxidative response of neutrophils from melanoma, colorectal and breast tumor patients. Int J Immunopharmacol 19(8):413–420PubMedCrossRef
403.
Godleski JJ, Lee RE, Leighton J (1970) Studies on the role of polymorphonuclear leukocytes in neoplastic disease with the chick embryo and Walker carcinosarcoma 256 in vivo and in vitro. Cancer Res 30(7):1986–1993PubMed
404.
Pickaver AH, Ratcliffe NA, Williams AE, Smith H (1972) Cytotoxic effects of peritoneal neutrophils on a syngeneic rat tumour. Nat New Biol 235(58):186–187PubMedCrossRef
405.
Fisher B, Saffer EA (1978) Tumor cells cytotoxicity by granulocytes from peripheral blood of tumor-bearing mice. J Natl Cancer Inst 60(3):687–691PubMed
406.
Nathan CF, Brukner LH, Silverstein SC, Cohn ZA (1979) Extracellular cytolysis by activated macrophages and granulocytes. I. Pharmacologic triggering of effector cells and the release of hydrogen peroxide. J Exp Med 149(1):84–99PubMedCrossRef
407.
Becker S, Haskill S (1980) Non-T-cell-mediated cytotoxicity in mice with tumors induced by Moloney murine sarcoma virus (M-MuSV). II. Granulocyte-mediatd cytotoxicity against autochthonous target cells isolated from M-MuSV-induced tumors. J Natl Cancer Inst 65(2):469–475PubMed
408.
Morikawa K, Kamegaya S, Yamazaki M, Mizuno D (1985) Hydrogen peroxide as a tumoricidal mediator of murine polymorphonuclear leukocytes induced by a linear beta-1,3-D-glucan and some other immunomodulators. Cancer Res 45(8):3482–3486PubMed
409.
Morikawa K, Takeda R, Yamazaki M, Mizuno D (1985) Induction of tumoricidal activity of polymorphonuclear leukocytes by a linear beta-1,3-D-glucan and other immunomodulators in murine cells. Cancer Res 45(4):1496–1501PubMed
410.
Lichtenstein AK, Kahle J, Berek J, Zighelboim J (1984) Successful immunotherapy with intraperitoneal Corynebacterium parvum in a murine ovarian cancer model is associated with the recruitment of tumor-lytic neutrophils into the peritoneal cavity. J Immunol 133(1):519–526PubMed
411.
Hirose K, Hakozaki M, Nyunoya Y, Kobayashi Y, Matsushita K, Takenouchi T, Mikata A, Mukaida N, Matsushima K (1995) Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration. Br J Cancer 72(3):708–714PubMedPubMedCentralCrossRef
412.
Chen RL, Reynolds CP, Seeger RC (2000) Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating. Cancer Immunol Immunother 48(11):603–612PubMedCrossRef
413.
Lozupone F, Luciani F, Venditti M, Rivoltini L, Pupa S, Parmiani G, Belardelli F, Fais S (2000) Murine granulocytes control human tumor growth in SCID mice. Int J Cancer 87(4):569–573PubMedCrossRef
414.
415.
416.
417.
Ibata M, Takahashi T, Shimizu T, Inoue Y, Maeda S, Tashiro-Yamaji J, Okada M, Ueda K, Kubota T, Yoshida R (2011) Spontaneous rejection of intradermally transplanted non-engineered tumor cells by neutrophils and macrophages from syngeneic strains of mice. Microbiol Immunol 55(10):726–735. doi:10.​1111/​j.​1348-0421.​2011.​00369.​x PubMedCrossRef
418.
419.
Clark RA, Klebanoff SJ, Einstein AB, Fefer A (1975) Peroxidase-H2O2-halide system: cytotoxic effect on mammalian tumor cells. Blood 45(2):161–170PubMed
420.
Clark RA, Olsson I, Klebanoff SJ (1976) Cytotoxicity for tumor cells of cationic proteins from human neutrophil granules. J Cell Biol 70(3):719–723PubMedCrossRef
421.
422.
Mikami M, Yamazaki M, Yui S (1998) Kinetical analysis of tumor cell death-inducing mechanism by polymorphonuclear leukocyte-derived calprotectin: involvement of protein synthesis and generation of reactive oxygen species in target cells. Microbiol Immunol 42(3):211–221PubMedCrossRef
423.
424.
Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, Widmann WD (2012) Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol 19(1):217–224. doi:10.​1245/​s10434-011-1814-0 PubMedCrossRef
425.
426.
Tibaldi C, Vasile E, Bernardini I, Orlandini C, Andreuccetti M, Falcone A (2008) Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model. J Cancer Res Clin Oncol 134(10):1143–1149. doi:10.​1007/​s00432-008-0378-2 PubMedCrossRef
427.
Satomi A, Murakami S, Ishida K, Mastuki M, Hashimoto T, Sonoda M (1995) Significance of increased neutrophils in patients with advanced colorectal cancer. Acta Oncol 34(1):69–73PubMedCrossRef
428.
Shibutani M, Maeda K, Nagahara H, Noda E, Ohtani H, Nishiguchi Y, Hirakawa K (2013) A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer. Anticancer Res 33(8):3291–3294PubMed
429.
430.
He W, Yin C, Guo G, Jiang C, Wang F, Qiu H, Chen X, Rong R, Zhang B, Xia L (2013) Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med Oncol 30(1):439. doi:10.​1007/​s12032-012-0439-x PubMedCrossRef
431.
432.
433.
Can C, Baseskioglu B, Yilmaz M, Colak E, Ozen A, Yenilmez A (2012) Pretreatment parameters obtained from peripheral blood sample predicts invasiveness of bladder carcinoma. Urol Int 89(4):468–472. doi:10.​1159/​000343278 PubMedCrossRef
434.
Perisanidis C, Kornek G, Poschl PW, Holzinger D, Pirklbauer K, Schopper C, Ewers R (2013) High neutrophil-to-lymphocyte ratio is an independent marker of poor disease-specific survival in patients with oral cancer. Med Oncol 30(1):334. doi:10.​1007/​s12032-012-0334-5 PubMedCrossRef
435.
436.
Sato H, Tsubosa Y, Kawano T (2012) Correlation between the pretherapeutic neutrophil to lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in patients with advanced esophageal cancer. World J Surg 36(3):617–622. doi:10.​1007/​s00268-011-1411-1 PubMedCrossRef
437.
438.
439.
440.
Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, Clarke SJ (2010) High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 16(23):5805–5813. doi:10.​1158/​1078-0432.​CCR-10-2245 PubMedCrossRef
441.
Kao SC, Klebe S, Henderson DW, Reid G, Chatfield M, Armstrong NJ, Yan TD, Vardy J, Clarke S, van Zandwijk N, McCaughan B (2011) Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol 6(11):1923–1929. doi:10.​1097/​JTO.​0b013e31822a3740​ PubMedCrossRef
442.
443.
Metadata
Title
The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment
Authors
Ronit Vogt Sionov
Zvi G. Fridlender
Zvi Granot
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Cancer Microenvironment / Issue 3/2015
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-014-0147-5

Other articles of this Issue 3/2015

Cancer Microenvironment 3/2015 Go to the issue

OriginalPaper

IL-1 in Colon Inflammation, Colon Carcinogenesis and Invasiveness of Colon Cancer

Original Paper

Tumour Microenvironment: Overview with an Emphasis on the Colorectal Liver Metastasis Pathway

Original Paper

The Role of Mast Cells in Molding the Tumor Microenvironment

Original Paper

Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV

Original Article

Stroma as an Active Player in the Development of the Tumor Microenvironment

OriginalPaper

Preface
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits